BioMedNewsBreaks Archive - Page 35 of 256

MondayJun 30, 2025 9:30 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review…

MondayJun 30, 2025 9:20 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Issues CEO Update, Reaffirms Commitment to Growth Following Leadership Transition

NextPlat (NASDAQ: NXPL, NXPLW) released a shareholder letter from Interim CEO expressing confidence in the company’s future following the recent passing of CEO and Chairman Charles M. Fernandez. The letter highlights internal reviews, meetings with subsidiary leaders, and plans for increased focus, coordination, and strategic investment to build on the company’s existing foundation and drive long-term value creation. To view the full press release, visit: https://ibn.fm/jGgfX About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist…

FridayJun 27, 2025 10:20 am

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotech company developing systemic oncolytic targeted immunotherapies, released a shareholder letter from CEO Eric Poma, PhD, outlining a transformative year for the company. Since Poma’s appointment in April 2025 and the addition of Dr. Guy Travis Clifton as Chief Medical Officer, Calidi has streamlined operations and advanced its RedTail platform—a systemically delivered virotherapy designed to target metastatic cancers and deliver genetic payloads. Preclinical data presented at AACR and ASCO showcased RedTail’s tumor selectivity and immune modulation potential, driving partnership discussions and IND-enabling studies for lead candidate CLD-401, with a filing expected by end…

ThursdayJun 26, 2025 3:53 pm

BioMedNewsBreaks — Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

Adageis offers providers tools that simplify operations and improve financial performance as healthcare shifts further toward value-based care. “One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards,” reads a recent article. “Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims…

ThursdayJun 26, 2025 11:43 am

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics(TM), Inc., has signed a binding Letter of Intent to acquire a 49% interest in Cohen and Associates, LLC, a top interventional psychiatry clinic founded by Dr. Rebecca Cohen in the Sarasota-Bradenton region. The clinic offers advanced treatments for suicidal depression, PTSD, and CNS disorders, including ketamine, Spravato, and TMS. The deal aims to establish a foundational clinic for HOPE’s regional growth and reflects its mission to deliver compassionate, evidence-based mental health care. Final terms remain subject to closing and definitive agreements. To view the full press release, visit https://ibn.fm/oaccX…

ThursdayJun 26, 2025 9:30 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Srl has won the "Oscar of Italian Dermatology" from SIDeMaST for her research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The study, published under the title "Blocking soluble Fas Ligand ameliorates pemphigus", confirms PC111’s ability to block blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris. Scinai holds an option to acquire Pincell and is advancing PC111 as a lead asset, emphasizing its potential as a non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions. To view the full press release,…

WednesdayJun 25, 2025 10:14 am

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Partners with Endlink to Advance Hospital Data Integration

HealthLynked (OTCQB: HLYK), a healthcare technology and patient engagement company, has announced a strategic partnership with Endlink, a data integration firm led by Rubén Viera. The alliance aims to enhance EMR connectivity and workflow automation across hospital systems, building on Endlink's success in Puerto Rico, where its platform serves over 300,000 members and supports two major hospital systems. Viera, a former executive at McKesson and Greenway Health, brings over 25 years of experience in healthcare IT and will help expand HealthLynked’s capabilities in real-time data integration and patient-centered care. The collaboration also creates opportunities to deploy HealthLynked's tools—like AI-driven insights…

WednesdayJun 25, 2025 9:15 am

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Expands Fingerprint Drug Testing Across Scandinavia with Spjotgard Partnership

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology firm specializing in non-invasive drug screening, reported continued success in its partnership with Spjotgard, a Scandinavian distributor. The collaboration is accelerating adoption of INBS’ fingerprint-based Drug Screening System across Sweden, Norway, and Denmark, with Finland showing rising interest. The technology offers a less invasive, hygienic alternative to urine and saliva tests, delivering results in under 10 minutes and gaining traction in sectors like logistics, education, and criminal justice. Spjotgard’s growing regional presence and strategic alliances position INBS to scale further in Northern Europe. To view the full article, visit https://ibn.fm/meqb1 About Intelligent…

TuesdayJun 24, 2025 3:28 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar

CNS Pharmaceuticals (NASDAQ: CNSP) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Erin Dunbar, Director of Neuro-Oncology at Piedmont Atlanta Hospital and founding physician of its Brain Tumor Center. Dr. Dunbar discussed the patient journey and current treatment options for Glioblastoma Multiforme (GBM), highlighting CNS’s lead product candidate, TPI 287, and its therapeutic potential for GBM and future metastatic tumor indications. To view the full press release, visit https://ibn.fm/cizlr About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of…

TuesdayJun 24, 2025 2:46 pm

BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company developing small molecule drug candidates for diseases with high unmet medical needs, announced new preclinical data showing that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation. The compound demonstrated a dose-dependent and statistically significant reduction in pro-inflammatory cytokines IL-6, IL-1β, IL-2, KC/Gro, and inflammasome marker NLRP3—key factors in Alzheimer’s disease progression. Notably, the effects were independent of amyloid beta or tau pathology, highlighting INM-901’s broader potential in treating neurodegenerative diseases. The orally administered compound also targets CB1/CB2 receptors and PPARs and has shown improvements in cognition and behavior in long-term animal…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Issues CEO Update, Reaffirms Commitment to Growth Following Leadership Transition

BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Highlights 2025 Pipeline Progress and Strategic Focus in Shareholder Letter

BioMedNewsBreaks — Adageis Brings Key Advantages in Pivot to Value-Based Healthcare

BioMedNewsBreaks — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire 49% Stake in Leading Florida Psychiatry Clinic

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award

BioMedNewsBreaks — HealthLynked Corp. (OTCQB: HLYK) Partners with Endlink to Advance Hospital Data Integration

BioMedNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Expands Fingerprint Drug Testing Across Scandinavia with Spjotgard Partnership

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights GBM Treatment Insights in KOL Segment Featuring Dr. Erin Dunbar

BioMedNewsBreaks — InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Positive Preclinical Results for INM-901 in Alzheimer’s Neuroinflammation Model

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search